Burning Rock Biotech (NASDAQ:BNR) Director Acquires $199,200.00 in Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han purchased 24,900 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was bought at an average price of $8.00 per share, with a total value of $199,200.00. Following the completion of the purchase, the director owned 18,404,086 shares of the company’s stock, valued at approximately $147,232,688. This represents a 0.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Yusheng Han also recently made the following trade(s):

• On Wednesday, June 24th, Yusheng Han purchased 250,000 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $8.00 per share, with a total value of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han acquired 5,990 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $7.50 per share, with a total value of $44,925.00.
• On Monday, June 22nd, Yusheng Han acquired 104,650 shares of Burning Rock Biotech stock. The shares were purchased at an average price of $7.45 per share, for a total transaction of $779,642.50.
• On Tuesday, June 16th, Yusheng Han bought 111,110 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $9.00 per share, for a total transaction of $999,990.00.
• On Friday, June 12th, Yusheng Han bought 210,000 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $9.25 per share, for a total transaction of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han bought 24,760 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $8.74 per share, with a total value of $216,402.40.

Burning Rock Biotech Stock Performance

Burning Rock Biotech stock opened at $9.82 on Friday. Burning Rock Biotech Limited Sponsored ADR has a 52 week low of $3.23 and a 52 week high of $41.72. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.81 and a current ratio of 3.05. The stock has a market capitalization of $103.31 million, a P/E ratio of -11.98 and a beta of 1.32. The stock has a 50-day simple moving average of $12.35 and a 200 day simple moving average of $19.96.

Burning Rock Biotech (NASDAQ:BNR) last released its quarterly earnings data on Tuesday, June 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.29) by $2.09. The firm had revenue of $15.66 million for the quarter, compared to analyst estimates of $19.21 million. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.

Analysts Set New Price Targets

BNR has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. Wall Street Zen cut shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Crcm LP lifted its position in Burning Rock Biotech by 13.8% during the third quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after acquiring an additional 26,809 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Burning Rock Biotech in the fourth quarter valued at approximately $220,000. Renaissance Technologies LLC grew its position in shares of Burning Rock Biotech by 13.8% in the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after purchasing an additional 4,290 shares during the last quarter. Finally, Prospera Financial Services Inc increased its stake in shares of Burning Rock Biotech by 26.0% during the fourth quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after purchasing an additional 6,430 shares during the period. 30.03% of the stock is owned by institutional investors.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.